Clinical impact of 11C-methionine PET on expected management of patients with brain neoplasm
Authors:
- 14 November 2009
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 37 (4) , 685-690
Abstract
We retrospectively examined the clinical efficacy of 11C-methionine positron emission tomography (11C-MET PET) in patients with brain neoplasm, especially whether the 11C-MET PET changed the clinical management and whether the change was beneficial or detrimental. This study reviewed 89 11C-MET PET scans for 80 patients (20 scans for initial diagnosis of brain tumor and 69 scans for differentiating tumor recurrence from radiation necrosis). Final diagnosis and the effect on the intended management were obtained from the questionnaire to the referring physicians or directly from the medical records. The diagnostic sensitivity, specificity, and accuracy for the 11C-MET PET were evaluated. Regarding the management impact, the rate of scans that caused changes in intended management was also evaluated. Moreover, the occurrence of scans having detrimental diagnostic impact (DDI) and beneficial diagnostic impact (BDI) were evaluated. Sensitivity, specificity, and accuracy of 11C-MET PET was 87.8, 80.0, and 85.9%. The intended management was changed in 50.0% of the scans. DDI and BDI were observed in 4.3 and 36.2% of the total relevant scans, respectively. 11C-MET PET can provide useful information in initial diagnosis and differentiating tumor recurrence from radiation necrosis. The intended management was changed in half of the scans. Since a few cases did not receive the requisite treatment due to false-negative results of 11C-MET PET, management decision should be made carefully, especially in the case of a negative scan.Keywords
This publication has 34 references indexed in Scilit:
- Clinical Value of Whole-body FDG-PET for Recurrent Gastric Cancer: A Multicenter StudyJapanese Journal of Clinical Oncology, 2009
- Analysis of11C-methionine Uptake in Low-Grade Gliomas and Correlation with Proliferative ActivityAmerican Journal of Neuroradiology, 2008
- 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed gliomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Evaluation of Primary Brain Tumors Using 11C-Methionine PET with Reference to a Normal Methionine Uptake MapJournal of Nuclear Medicine, 2007
- Integrated positron emission tomography and magnetic resonance imaging–guided resection of brain tumors: a report of 103 consecutive proceduresJournal of Neurosurgery, 2006
- Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography—guided stereotactic brain biopsiesJournal of Neurosurgery, 2004
- Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible?Journal of Neurosurgery, 2003
- Cranial Neuronavigation with Direct Integration of 11 C Methionine Positron Emission Tomography (PET) Data - Results of a Pilot Study in 32 Surgical CasesActa Neurochirurgica, 2002
- Positron emission tomography with injection of methionine as a prognostic factor in gliomaJournal of Neurosurgery, 2001
- Correlation between Magnetic Resonance Spectroscopy Imaging and Image-guided Biopsies: Semiquantitative and Qualitative Histopathological Analyses of Patients with Untreated GliomaNeurosurgery, 2001